Platelet Derived Growth Factor Receptor- Alpha D842v Mutation in a Spindle Cell Type Gastrointestinal Stromal Tumor: A Case Report

Authors

  • Jenissa Amor Arceño St. Luke's Medical Center Quezon City
  • Kathleen Chua Chinese General Hospital
  • Loraine Kay Cabral St. Luke's Medical Center Quezon City
  • Arlie Jean Grace Dumasis St. Luke's Medical Center - Global City
  • Jose Jasper Andal St. Luke's Medical Center, Quezon City
  • Raymundo Lo St. Luke's Medical Center, Quezon City
  • Glenda Lyn Pua St. Luke's Medical Center, Quezon City
  • Daphne Ang Institute of Pathology, St. Luke's Medical Center Quezon City

Keywords:

gastrointestinal stromal tumor (GIST), platelet derived growth factor receptor-alpha (PDGFRA)

Abstract

Molecular genotyping of gastrointestinal stromal tumors is not yet available in the Philippines. We report a case of a 75-year old male with a gastric submucosal mass, who underwent gastroscopic/laparoscopic wedge resection. Histopathology and subsequent immunohistochemical staining with CD117 (CKIT) and DOG1 revealed diagnosis of gastrointestinal stromal tumor, spindle cell variant. On genotyping, the tumor harbored PDGFRA D842V mutation, a subtype resistant to Imatinib treatment. 

Downloads

Download data is not yet available.

Author Biographies

Jenissa Amor Arceño, St. Luke's Medical Center Quezon City

Pathology resident

Kathleen Chua, Chinese General Hospital

Surgery Resident

Loraine Kay Cabral, St. Luke's Medical Center Quezon City

Scientist

 

Arlie Jean Grace Dumasis, St. Luke's Medical Center - Global City

Medical Technologist

Jose Jasper Andal, St. Luke's Medical Center, Quezon City

Pathologist

Raymundo Lo, St. Luke's Medical Center, Quezon City

Pathologist

Glenda Lyn Pua, St. Luke's Medical Center, Quezon City

Pathologist

Daphne Ang, Institute of Pathology, St. Luke's Medical Center Quezon City

Pathologist

References

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Path Lab Med. 2006;130(10)1466-78. PMID: 17090188.

2. Pogorzelski M, Falkenhorst J, Bauer S. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Curr Opin Oncol. 2016;28(4):331-7. PMID: 27163723. https://doi.org/10.1097/CCO.0000000000000303.

3. Xu Z, Huo X, Tang C, et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep. 2014;4:5907. PMID: 25080996. PMCID: PMC4118194.https://doi.org/10.1038/srep05907.

4. Comandone A, Boglione A. The importance of mutational status in prognosis and therapy of GIST. Recenti Prog Med. 2015;106(1):17-22. PMID: 25621775. https://doi.org/10.1701/1740.18950.

5. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-9. PMID: 14645423. https://doi.org/10.1200/JCO.2003.04.190.

6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumor: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate ear – a population-based study in western Sweden. Cancer. 2005;103(4):821-9. PMID: 15648083. https://doi.org/10.1002/cncr.20862.

7. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66. PMID: 18312355. https://doi.org/10.1111/j.1365-2559.2008.02977.x.

8. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012;29(3):1765–72. PMID: 21953054. https://doi.org/10.1007/s12032-011-0074-y.

9. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010; 103(2):165–70. PMCID: PMC2906738. https://doi.org/10.1038/sj.bjc.6605743.

10. Liang YM, Li XH, Lü YY, Lü YL, Zhong M, Pu XL, Li WM. Prognostic significance of clinicopathologic parameters in gastrointestinal stromal tumor: a study of 156 cases. Zhonghua Bing Li Xue Za Zhi. 2007;36(4):233-8. PMID: 17706113.
11. Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment and future directions. ISRN Gastroenterol. 2012 2012: 595968. PMID: 22577569. PMCID: PMC3332214. https://doi.org/10.5402/2012/595968.

12. Corless CL, Shroeder A, Griffith D, et al. PDGFRA mutations in GISTs: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357-64. PMID: 15928335. https://doi.org/10.1200/JCO.2005.14.068.

13. Yoo C, Ryu M, et al. Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors. Cancer Res Treat. 2016;48(2):546-52. PMCID: PMC4843750. https://doi.org/10.4143/crt.2015.015.

Published

02/07/2018

How to Cite

Arceño, J. A., Chua, K., Cabral, L. K., Dumasis, A. J. G., Andal, J. J., Lo, R., … Ang, D. (2018). Platelet Derived Growth Factor Receptor- Alpha D842v Mutation in a Spindle Cell Type Gastrointestinal Stromal Tumor: A Case Report. PJP, 3(1), 16. Retrieved from https://philippinejournalofpathology.org/index.php/PJP/article/view/87

Most read articles by the same author(s)

<< < 1 2 3 > >>